Skip to main content
SpringerLink
Log in

Salvage therapy with single agent bendamustine for recurrent glioblastoma

  • CLINICAL STUDY – PATIENT STUDY
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The treatment of recurrent glioblastoma (GBM) remains challenging notwithstanding the recent approval of bevacizumab for this indication. Bendamustine has a bifunctional mechanism of action including alkylation, penetrates the CNS and does not show cross resistance to other alkylator chemotherapies. In a single institution phase 2 trial, patients with recurrent GBM were treated with bendamustine (100 mg/m2/day administered intravenously for two consecutive days every 4 weeks). The primary study endpoint was 6-month progression free survival (PFS-6). An interim analysis for futility was conducted according to a Simon two-stage minimax design. Complete blood counts were obtained bimonthly, clinical evaluations and brain imaging every month for the first cycle and bimonthly thereafter. Treatment responses were based upon MacDonald criteria. Sixteen patients were enrolled (nine men; seven women), with a median age of 53 years (range 36–68) and a median Karnofsky performance status of 90 (range 70–100). Nine patients were treated at first relapse and seven at second relapse (five patients were bevacizumab failures). A total of 25 cycles of bendamustine were administered with a median of 1 (range 1–6). Bendamustine-related toxicity was seen in eight patients; lymphopenia in seven (5 grade 3; 2 Grade 4), thrombocytopenia in two (1 Grade 3; 1 Grade 4), and neutropenia in one (1 Grade 3). Fourteen patients have died due to disease progression, two patients are alive and on alternative therapies. Only one patient was progression-free at 6 months, triggering the stopping rule for futility. Bendamustine was reasonably well tolerated but failed to meet the study criteria for activity in adults with recurrent GBM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Adamson C, Kanu OO et al (2009) Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs 18(8):1061–1083

    Article  PubMed  CAS  Google Scholar 

  2. Brem H, Piantadosi S, Burger PC, Walker M, Selker R et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008–1012

    Article  PubMed  CAS  Google Scholar 

  3. Fogh SE, Andrews DW, Glass J et al (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 28(18):3048–3053

    Article  PubMed  Google Scholar 

  4. Carson KA, Grossman SA et al (2007) Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 25(18):2601–2606

    Article  PubMed  Google Scholar 

  5. Gerstner ER, Duda DG et al (2007) Antiangiogenic agents for the treatment of glioblastoma. Expert Opin Investig Drugs 16(12):1895–1908

    Article  PubMed  CAS  Google Scholar 

  6. Hou LCA, Veeravagu A et al (2006) Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus 20(4):E5

    Article  PubMed  Google Scholar 

  7. Yung WKA, Mechtler L, Gleason MJ (1991) Intravenous carboplatin for recurrent malignant gliomas: a phase II study. J Clin Oncol 9:860

    PubMed  CAS  Google Scholar 

  8. Iwamoto FM, Fine HA (2010) Bevacizumab for malignant gliomas. Arch Neurol 67(3):285–288

    Article  PubMed  Google Scholar 

  9. Reardon DA, Fink KL, Mikkelsen T et al (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine–glycine–aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26(34):5610–5617

    Article  PubMed  CAS  Google Scholar 

  10. Schmidt F, Fischer J, Herrlinger U et al (2006) PCV chemotherapy for recurrent glioblastoma. Neurology 66(4):587–589

    Article  PubMed  CAS  Google Scholar 

  11. Simpson L, Galanis E (2006) Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates. Expert Rev Anticancer Ther 6(11):1593–1607

    Article  PubMed  CAS  Google Scholar 

  12. Wick W, Puduvalli VK, Chamberlain MC et al (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28(7):1168–1174

    Article  PubMed  CAS  Google Scholar 

  13. Wick A, Pascher C, Wick W et al (2009) Rechallenge with temozolomide in patients with recurrent gliomas. J Neurol 256(5):734–741

    Article  PubMed  CAS  Google Scholar 

  14. See SJ, Levin VA, Yung A et al (2004) 13-cis-Retinoic acid in the treatment of recurrent glioblastoma multiforme. Neuro-Oncology 6:253–258

    Article  PubMed  CAS  Google Scholar 

  15. Chamberlain MC, Tsao-Wei D (2004) Recurrent glioblastoma multiforme: salvage therapy with cyclophosphamide. Cancer 100:1213–1220

    Article  PubMed  CAS  Google Scholar 

  16. Jaeckle KA, Hess KR, Yung A et al (2003) Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol 21:2305–2311

    Article  PubMed  CAS  Google Scholar 

  17. Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ (2008) Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther 8(4):541–553

    Article  PubMed  CAS  Google Scholar 

  18. Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83(5):588–593

    Article  PubMed  CAS  Google Scholar 

  19. Coombs SE, Bischof M, Welzel T et al (2008) Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. J Neurooncol 89(2):205–210

    Article  Google Scholar 

  20. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492–507

    Article  PubMed  CAS  Google Scholar 

  21. Park JK, Hodges T, Arko L. et al (2009) Scale to predict survival after surgery for recurrent glioblastoma multiforme. Presented in part at the Annual Meeting of the Congress of Neurological Surgeons, New Orleans, 24–29 October 2009

  22. Brada M, Stenning S, Gabe R et al (2010) Temozolomide versus procarbazine, lomustine and vincristine in recurrent high-grade glioma. J Clin Oncol 28:4601–4608

    Article  PubMed  CAS  Google Scholar 

  23. Reardon DA, Fink KL, Mikkelsen T et al (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine–glycine–aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26:5610–5617

    Article  PubMed  CAS  Google Scholar 

  24. Nabors LB, Mikkelsen T, Rosenfeld SS et al (2007) Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25(13):1651–1657

    Article  PubMed  CAS  Google Scholar 

  25. Perry JR, Belanger K, Mason WP et al (2010) Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE Study. J Clin Oncol 28(12):2051–2057

    Article  PubMed  CAS  Google Scholar 

  26. Ballman KV, Buckner JC, Brown PD et al (2007) The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro-Oncology 9:29–38

    Article  PubMed  CAS  Google Scholar 

  27. Lamborn KR, Yung AWK, Chang SM et al (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. J Neurooncol 10:162–170

    Google Scholar 

  28. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572–2578

    PubMed  CAS  Google Scholar 

  29. Bendamustine hydrochloride (CEP-18083) INVESTIGATOR’S BROCHURE, Cephalon Edition 2 Release Date: 4 March 2010

  30. Keating MJ, Bach C, Yasothan U, Kirkpatrick P (2008) Bendamustine. Nat Rev Drug Discov 7(6):473–474

    Article  PubMed  CAS  Google Scholar 

  31. Leoni LM, Bailey B, Reifert J et al (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14(1):309–317

    Article  PubMed  CAS  Google Scholar 

  32. Köster W, Stamatis G, Heider A et al (2004) Carboplatin in combination with bendamustine in previously untreated patients with extensive-stage small cell lung cancer (SCLC). Clin Drug Investig 24(10):611–618

    Article  PubMed  Google Scholar 

  33. Köster W, Heider A, Niederle N et al (2007) Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer. J Thorac Oncol 2(4):312–316

    Article  PubMed  Google Scholar 

  34. Eichbaum MH, Schuetz F, Khbeis T et al (2007) Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study. Anticancer Drugs 18(8):963–968

    PubMed  CAS  Google Scholar 

  35. Friedberg JW, Cohen P, Chen L et al (2008) Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 26(2):204–210

    Article  PubMed  CAS  Google Scholar 

  36. Lissitchkov T, Arnaudov G, Peytchev D, Merkle KH (2006) Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 132(2):99–104

    Article  PubMed  CAS  Google Scholar 

  37. Friedberg JW, Cohen P, Chen L et al (2008) Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 26(2):204–210

    Article  PubMed  CAS  Google Scholar 

  38. Zulkowski K, Kath R, Semrau R, Merkle KH, Höffken K (2002) Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine. J Cancer Res Clin Oncol 128:111–113

    Article  PubMed  CAS  Google Scholar 

  39. MacDonald DR, Cascino TL, Schold SC et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280

    PubMed  CAS  Google Scholar 

  40. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972

    Article  PubMed  Google Scholar 

  41. Cheson BD, Rummel M (2009) Bendamustine: rebirth of an old drug. J Clin Oncol 27(9):1492–1501

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Carrie Graham, RN, CNP, Maciej Mrugala, MD and Alexander Spence, MD for contributing patients to the study; Brenda Kurland, PhD for statistical consultation and manuscript review, and Sharon Larsson for editorial assistance.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Neurology and Neurosurgery, University of Washington/Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 825 Eastlake Ave E, Mailstop: G4-940, Seattle, WA, 98109, USA

    Marc C. Chamberlain & Sandra K. Johnston

Authors
  1. Marc C. Chamberlain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sandra K. Johnston
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc C. Chamberlain.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chamberlain, M.C., Johnston, S.K. Salvage therapy with single agent bendamustine for recurrent glioblastoma. J Neurooncol 105, 523–530 (2011). https://doi.org/10.1007/s11060-011-0612-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-011-0612-7

Keywords

Search

Navigation